SavedAdd your journal

Journals / Hacettepe Üniversitesi Eczacılık Fakültesi Dergisi / 2023 / Cilt: 43 Sayı: 3

Evaluation of Renal Effects of Dapagliflozin in Diabetic Rats with Subacute Exposure

Evaluation of Renal Effects of Dapagliflozin in Diabetic Rats With Subacute Exposure

Tugce BORAN
Bahar ULUS KARACA
Ayça KARAGÖZ KÖROĞLU
Feriha ERCAN
Gül ÖZHAN
Pages
232–242
Publication Date
2023-09-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, further studies are needed to determine the long-term effects of DAPA on the kidney in diabetic patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:ABSTRACT Dapagliflozin (DAPA), a sodium glucose co-transporter 2 (SGLT2) inhibitor, is used for the treatment of type 2 diabetes.
📊
Key Findings & Data:Although several studies have demonstrated its protective effects on the kidney, the FDA warns about the risk of DAPA-induced nephrotoxicity.
💡
Conclusion & Impact:However, further studies are needed to determine the long-term effects of DAPA on the kidney in diabetic patients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Dapagliflozin · SGLT2 inhibitors · nephrotoxicity

Abstract

ABSTRACT Dapagliflozin (DAPA), a sodium glucose co-transporter 2 (SGLT2) inhibitor, is used for the treatment of type 2 diabetes. Although several studies have demonstrated its protective effects on the kidney, the FDA warns about the risk of DAPA-induced nephrotoxicity. SGLT2 inhibitors may induce oxidative stress and inflammation in the kidney due to their mechanism of action. In the present study, it was aimed to clarify the molecular effects of DAPA on the kidney. Diabetes was induced by single injection of streptozotocin (STZ) (35 mg/kg b.w.) after the rats were fed with high-fat diet for two-weeks. Diabetic rats were administered with DAPA at 10 mg/kg by oral gavage for 28 days. The oxidative stress, inflammation and apoptosis induction potentials of DAPA were evaluated. The morphological changes and apoptosis were investigated by histological examinations. The findings showed that DAPA treatment reduced oxidative parameters and slightly inhibited inflammatory mediator levels. According to the histological examinations, DAPA ameliorated the diabetes-induced changes and apoptosis. As a result, DAPA showed a protective effect on the kidney by alleviating oxidative stress and inhibiting inflammation and apoptosis. However, further studies are needed to determine the long-term effects of DAPA on the kidney in diabetic patients.

Özet

ABSTRACT Dapagliflozin (DAPA), a sodium glucose co-transporter 2 (SGLT2) inhibitor, is used for the treatment of type 2 diabetes. Although several studies have demonstrated its protective effects on the kidney, the FDA warns about the risk of DAPA-induced nephrotoxicity. SGLT2 inhibitors may induce oxidative stress and inflammation in the kidney due to their mechanism of action. In the present study, it was aimed to clarify the molecular effects of DAPA on the kidney. Diabetes was induced by single injection of streptozotocin (STZ) (35 mg/kg b.w.) after the rats were fed with high-fat diet for two-weeks. Diabetic rats were administered with DAPA at 10 mg/kg by oral gavage for 28 days. The oxidative stress, inflammation and apoptosis induction potentials of DAPA were evaluated. The morphological changes and apoptosis were investigated by histological examinations. The findings showed that DAPA treatment reduced oxidative parameters and slightly inhibited inflammatory mediator levels. According to the histological examinations, DAPA ameliorated the diabetes-induced changes and apoptosis. As a result, DAPA showed a protective effect on the kidney by alleviating oxidative stress and inhibiting inflammation and apoptosis. However, further studies are needed to determine the long-term effects of DAPA on the kidney in diabetic patients.

🔖

Cite This Article

BORAN, T., KARACA, B. U., KÖROĞLU, A. K., ERCAN, F., ÖZHAN, G. (2023). Evaluation of Renal Effects of Dapagliflozin in Diabetic Rats with Subacute Exposure. Hacettepe Üniversitesi Eczacılık Fakültesi Dergisi, Cilt: 43 Sayı: 3, 232–242. https://ajindex.com/articles/961331

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. FDA, 2014. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202293s003lbl.pdf. (accessed 5 January 2020)
  2. FDA, 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209091s002lbl.pdf. (accessed 5 January 2020)
  3. FDA 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202293s024lbl.pdf (accessed 10 June 2020)
  4. Joe E. 2019. Dapagliflozin approved to reduce risk for heart failure hospitalization in type 2 diabetes. NEJM J Watch 2019. https://www.jwatch.org/fw115953/2019/10/22/dapagliflozin-approved-reduce-risk-heart-failure. (accessed 30 January 2020)
  5. FDA, 2016. FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR) | https://www.fda.gov/drugs/fda-drug-safety-podcasts/fda-strengthens-kidney-warnings-diabetes-medicines-canagliflozin-invokana-invokamet-and (accessed January 5, 2020)
  6. Pleros C, Stamaki E, Papadaki A, Damianakis N, Poulidaki R, Gakiopoolou C, Tzanakis I: Dapagliflozin as a cause of acute tubular necrosis with heavy consequences: a case report. CEN Case Reports, 2018, 7:17–20
  7. Lim S, Eckel RH, and Koh KK: Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors. Atherosclerosis, 2018, 272:33–40
  8. Garofalo C, Borrelli S, Liberti ME, Andreucci M, Conte G, Minutolo R, Provenzano M, De Nicola L: SGLT2 inhibitors: nephroprotective efficacy and side effects. Medicina, 2019, 55(6):268
  9. Baker ML, and Perazella MA: SGLT2 inhibitor therapy in patients with type-2 diabetes mellitus: is acute kidney injury a concern?. Journal of Nephrolology. 2020, 33:985-994
  10. McMurray JJ, Wheeler DC, Stefánsson BV, Jongs N, Postmus D, Correa-Rotter R: DAPA-CKD Trial Committees and Investigators. (2021). Effect of dapagliflozin on clinical outcomes in patients with chronic kidney disease, with and without cardiovascular disease. Circulation, 2021, 143(5):438-448
  11. Srinivasan K, Wiswanad B, Asrat L, Kaul CL, Ramarao P: Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacological Research, 2005, 52:313–320
  12. Furman BL: Streptozotocin induced diabetic models in mice and rats. Current Protocols in Pharmacology. 2015, 70: 5-47
  13. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 2001; 25:402–408
  14. Hahn K, Ejaz